Adapt Out COVID

Adapt Out COVID is a study to evaluate the safety and efficacy of investigational agents for the treatment of non-hospitalized adults with COVID-19 symptoms. 

Study phase: II

Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.

Adults 18 years and older; Signed informed consent; Positive test for COVID-19 up to 7 days before participation in study; Able to begin study treatment no later than 10 days from self-reported onset of COVID-19 related symptom(s) including fever or feeling feverish, cough, shortness of breath or difficulty, breathing at rest or when active, sore throat, body pain or muscle pain/aches, fatigue, headache, chills, blocked nose/nasal congestion, runny nose, loss of taste or smell, nausea or vomiting, diarrhea, temperature ≥ 38 C (100.4°F); Symptomatic within 48 hours of participating in the study; Oxygen levels of ≥92% when resting (measured by study staff within 48 hours of participating in the study), unless participant is receiving long-term supplementary oxygen for an underlying lung condition; Participant must agree not to participate in another clinical trial for the treatment of COVID-19 or SARS-CoV-2 during the study period until hospitalization or 28 days after the start of the study, whichever occurs first. 

Additional information:

For more information visit www.activ-2.org

Primary disease category: HIV/AIDS & Infectious Disease

Secondary disease categories: Asthma & Lung, COVID-19

Sponsor: National Institute of Allergy and Infectious Diseases

Protocol number: ACTIV-2

Projected enrollment dates: September 2020 to February 2021

Official study title: ACTIV-2: Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID)